**14.3 TBA-7371**

*Molecular Epidemiology Study of Mycobacterium Tuberculosis Complex*

**Possible adverse effects**

Isoniazid Hepatotoxicity, dermatological, gastrointestinal, hypersensitivity

Rifampicin Heartburn, epigastric distress, Thrombocytopenia,

Ethambutol Retrobulbar neuritis, gastrointestinal disturbance. Pyrazinamide GI disturbances, Thrombocytopenia, sideroblastic anemia, Mild arthralgia myalgia etc.

Streptomycin burning, crawling, itching, numbness, prickling etc.

Amikacin diarrhea, hearing loss, spinning sensation (vertigo),

Levofloxacin low blood sugar, headache, hunger, sweating, irritability

Gatifloxacin red, irritated, itchy, or teary eyes, blurred vision, eye pain

Ethionamide Nausea, vomiting, diarrhea, abdominal/stomach pain etc.

persistent nausea, vomiting and diarrhea etc.

fungal infections, low platelet counts etc.

Cycloserine Headache, drowsiness, dizziness, or shaking etc.

Linezolid severe diarrhea or diarrhea that is watery or bloody,

Redaquiline Nausea / Vomiting, Dizziness, Headache, Hemoptysis etc. Clofazimine diarrhea, nausea, vomiting, gastrointestinal intolerance

Amoxicillin severe skin rash, itching, hives, difficulty breathing or

High dose Isoniazid increased blood levels of liver enzymes and numbness

swallowing etc.

numbness etc.

etc.

Kanamicin pain or irritation

Fluroquinol drugs Ofloxacin Nausea, diarrhea, constipation, gas, vomiting etc.

etc.

etc.

Prothionamide depression and hallucinations

etc.

etc.

p-Aminosalicylic

acid

*Current mode of therapy and therapeutic drugs for tuberculosis.*

Leukopenia, hemolytic anemia, Menstrual disturbances

**Mode of therapy Implemented** 

First line oral agents (Ref. 33, 34)

Injectable anti-TB

Second line oral drugs

Anti-TB drugs with long term safety

drugs

**Drugs**

mode of action and efficacy of SQ109 differ widely from ethambutol [57, 58]. SQ109 is bactericidal in nature and works by targeting a transmembrane transport protein MmpL3 which is responsible for transmitting trehalose monomicolate during cell wall synthesis [59, 60]. It acts against extracellular as well as intracellular bacilli and works on acute and chronic mouse models of tuberculosis infection [61]. SQ109 improved the pharmacological efficacy of the present four available first-line drugs against tuberculosis and represents synergy with Sirturo. It is presently under phase

It is an amide compound of imidazopyridine and was recognized by the whole-cell screening of infected macrophages [17]. Q203 prevents ATP synthesis via causing an

**20**

**14.2 Q203**

**Table 2.**

2 clinical studies [5, 15].

A member of a series of 1,4-azaindole which was recognized by a strategy of transformation of scaffolds preceded by a program of optimization of lead of a compound imidazopyridine [62]. TBA-7371 inhibits DprE1 non-covalently, a decaprenyl phosphoryl-β-Dribose2′-epimerase, in cell wall Arabian biosynthetic pathway. TBA-7371 is bactericidal and is working against both acute and chronic mouse models of tuberculosis infection. It is under phase 1 clinical studies [3, 46, 57].
